229 related articles for article (PubMed ID: 30071291)
1. Advances in targeting epidermal growth factor receptor signaling pathway in mammary cancer.
Kyriakopoulou K; Kefali E; Piperigkou Z; Bassiony H; Karamanos NK
Cell Signal; 2018 Nov; 51():99-109. PubMed ID: 30071291
[TBL] [Abstract][Full Text] [Related]
2. Growth and molecular interactions of the anti-EGFR antibody cetuximab and the DNA cross-linking agent cisplatin in gefitinib-resistant MDA-MB-468 cells: new prospects in the treatment of triple-negative/basal-like breast cancer.
Oliveras-Ferraros C; Vazquez-Martin A; López-Bonet E; Martín-Castillo B; Del Barco S; Brunet J; Menendez JA
Int J Oncol; 2008 Dec; 33(6):1165-76. PubMed ID: 19020749
[TBL] [Abstract][Full Text] [Related]
3. Advances in Targeting the Epidermal Growth Factor Receptor Pathway by Synthetic Products and Its Regulation by Epigenetic Modulators As a Therapy for Glioblastoma.
Nadeem Abbas M; Kausar S; Wang F; Zhao Y; Cui H
Cells; 2019 Apr; 8(4):. PubMed ID: 31013819
[TBL] [Abstract][Full Text] [Related]
4. Disulfide bond disrupting agents activate the unfolded protein response in EGFR- and HER2-positive breast tumor cells.
Ferreira RB; Wang M; Law ME; Davis BJ; Bartley AN; Higgins PJ; Kilberg MS; Santostefano KE; Terada N; Heldermon CD; Castellano RK; Law BK
Oncotarget; 2017 Apr; 8(17):28971-28989. PubMed ID: 28423644
[TBL] [Abstract][Full Text] [Related]
5. Extracellular matrix protein 1 regulates cell proliferation and trastuzumab resistance through activation of epidermal growth factor signaling.
Lee KM; Nam K; Oh S; Lim J; Kim YP; Lee JW; Yu JH; Ahn SH; Kim SB; Noh DY; Lee T; Shin I
Breast Cancer Res; 2014 Dec; 16(6):479. PubMed ID: 25499743
[TBL] [Abstract][Full Text] [Related]
6. Estrogen receptor beta as epigenetic mediator of miR-10b and miR-145 in mammary cancer.
Piperigkou Z; Franchi M; Götte M; Karamanos NK
Matrix Biol; 2017 Dec; 64():94-111. PubMed ID: 28797712
[TBL] [Abstract][Full Text] [Related]
7. EGFR-mediated autophagy in tumourigenesis and therapeutic resistance.
Wu M; Zhang P
Cancer Lett; 2020 Jan; 469():207-216. PubMed ID: 31639425
[TBL] [Abstract][Full Text] [Related]
8. ΕGFR/ERβ-Mediated Cell Morphology and Invasion Capacity Are Associated with Matrix Culture Substrates in Breast Cancer.
Kyriakopoulou K; Riti E; Piperigkou Z; Koutroumanou Sarri K; Bassiony H; Franchi M; Karamanos NK
Cells; 2020 Oct; 9(10):. PubMed ID: 33050027
[TBL] [Abstract][Full Text] [Related]
9. Autocrine WNT signaling contributes to breast cancer cell proliferation via the canonical WNT pathway and EGFR transactivation.
Schlange T; Matsuda Y; Lienhard S; Huber A; Hynes NE
Breast Cancer Res; 2007; 9(5):R63. PubMed ID: 17897439
[TBL] [Abstract][Full Text] [Related]
10. Effect of epidermal growth factor receptor inhibitor on development of estrogen receptor-negative mammary tumors.
Lu C; Speers C; Zhang Y; Xu X; Hill J; Steinbis E; Celestino J; Shen Q; Kim H; Hilsenbeck S; Mohsin SK; Wakeling A; Osborne CK; Brown PH
J Natl Cancer Inst; 2003 Dec; 95(24):1825-33. PubMed ID: 14679152
[TBL] [Abstract][Full Text] [Related]
11. MicroRNAs as a drug resistance mechanism to targeted therapies in EGFR-mutated NSCLC: Current implications and future directions.
Leonetti A; Assaraf YG; Veltsista PD; El Hassouni B; Tiseo M; Giovannetti E
Drug Resist Updat; 2019 Jan; 42():1-11. PubMed ID: 30544036
[TBL] [Abstract][Full Text] [Related]
12. [Involvement of epidermal growth factor receptor signaling pathway in tamoxifen resistance of MCF-7 cells].
Zhen LL; Zhu X; Zheng W; Wang XY; Wu ZY
Ai Zheng; 2006 Jul; 25(7):839-43. PubMed ID: 16831274
[TBL] [Abstract][Full Text] [Related]
13. MiR-410 Acts as a Tumor Suppressor in Estrogen Receptor-Positive Breast Cancer Cells by Directly Targeting ERLIN2 via the ERS Pathway.
Wu H; Li J; Guo E; Luo S; Wang G
Cell Physiol Biochem; 2018; 48(2):461-474. PubMed ID: 30016800
[TBL] [Abstract][Full Text] [Related]
14. Cross-talk between estradiol receptor and EGFR/IGF-IR signaling pathways in estrogen-responsive breast cancers: focus on the role and impact of proteoglycans.
Skandalis SS; Afratis N; Smirlaki G; Nikitovic D; Theocharis AD; Tzanakakis GN; Karamanos NK
Matrix Biol; 2014 Apr; 35():182-93. PubMed ID: 24063949
[TBL] [Abstract][Full Text] [Related]
15. Studies of epidermal growth factor receptor inhibition in breast cancer.
Bundred NJ; Chan K; Anderson NG
Endocr Relat Cancer; 2001 Sep; 8(3):183-9. PubMed ID: 11566609
[TBL] [Abstract][Full Text] [Related]
16. Role of epidermal growth factor receptor in breast cancer.
Masuda H; Zhang D; Bartholomeusz C; Doihara H; Hortobagyi GN; Ueno NT
Breast Cancer Res Treat; 2012 Nov; 136(2):331-45. PubMed ID: 23073759
[TBL] [Abstract][Full Text] [Related]
17. Acquisition of epithelial-mesenchymal transition phenotype in the tamoxifen-resistant breast cancer cell: a new role for G protein-coupled estrogen receptor in mediating tamoxifen resistance through cancer-associated fibroblast-derived fibronectin and β1-integrin signaling pathway in tumor cells.
Yuan J; Liu M; Yang L; Tu G; Zhu Q; Chen M; Cheng H; Luo H; Fu W; Li Z; Yang G
Breast Cancer Res; 2015 May; 17(1):69. PubMed ID: 25990368
[TBL] [Abstract][Full Text] [Related]
18. Recent Advances on Epidermal Growth Factor Receptor as a Molecular Target for Breast Cancer Therapeutics.
Shetty SR; Yeeravalli R; Bera T; Das A
Anticancer Agents Med Chem; 2021; 21(14):1783-1792. PubMed ID: 33355057
[TBL] [Abstract][Full Text] [Related]
19. Overexpression of miR-361-5p in triple-negative breast cancer (TNBC) inhibits migration and invasion by targeting RQCD1 and inhibiting the EGFR/PI3K/Akt pathway.
Han J; Yu J; Dai Y; Li J; Guo M; Song J; Zhou X
Bosn J Basic Med Sci; 2019 Feb; 19(1):52-59. PubMed ID: 29924958
[TBL] [Abstract][Full Text] [Related]
20. Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers.
Roskoski R
Pharmacol Res; 2019 Jan; 139():395-411. PubMed ID: 30500458
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]